Difference between revisions of "MSK Biomarker Ctte"
Jump to navigation
Jump to search
| Line 11: | Line 11: | ||
*[[Media:2017_07-18_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|07.18.2017 QIBA MSK Biomarker Ctte Call Summary]] | *[[Media:2017_07-18_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|07.18.2017 QIBA MSK Biomarker Ctte Call Summary]] | ||
*[[Media:2017_06-20_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|06.20.2017 QIBA MSK Biomarker Ctte Call Summary]] | *[[Media:2017_06-20_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|06.20.2017 QIBA MSK Biomarker Ctte Call Summary]] | ||
| − | |||
| − | |||
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | ||
Revision as of 15:19, 3 November 2017
- Co-chairs: Thomas M. Link, MD, PhD; Xiaojuan Li, PhD
- Secretary: Susan Weinmann
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Recent Meetings/Call Summaries
- 09.19.2017 QIBA MSK Biomarker Ctte Call Summary
- 07.18.2017 QIBA MSK Biomarker Ctte Call Summary
- 06.20.2017 QIBA MSK Biomarker Ctte Call Summary
MSK Biomarker Committee Call Summaries Archive